BioAtla, which is developing antibody drugs, has hired Eric Sievers as its chief medical officer. He was most recently CMO at Toronto’s Trillium Therapeutics (NASDAQ: [[ticker:TRIL]]), according to a news release from BioAtla. Prior, Sievers spent nine years at Seattle Genetics (NASDAQ: [[ticker:SGEN]]), where he was involved in the development and approval of brentuximab vedotin (Adcetris) as a treatment for Hodgkin’s lymphoma, peripheral T-cell lymphoma, and cutaneous T-cell lymphoma. BioAtla, which has two programs in Phase 1/2 testing in the US, has operations in San Diego and Beijing.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
